Travere Therapeutics Inc
SWB:17R
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of 
Travere Therapeutics Inc (17R) under the Base Case is 18.83 EUR per share.
Compared with the current market price of 20.4 EUR, the stock appears
Overvalued by 8% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Travere Therapeutics Does
Travere Therapeutics is a biotechnology company focused on rare kidney and liver diseases. It develops and sells prescription medicines for patients with conditions that are too small or specialized for big drug makers to chase through broad primary-care marketing. Its current business centers on specialty drugs such as treatments for IgA nephropathy and cystinuria, along with research programs for other serious rare diseases.
- Headquarters
- United States of America US
- Employees
- 497
- IPO date
- Jul 23, 2003
Revenue & Expenses Breakdown
Travere Therapeutics Inc
Earnings Waterfall
Travere Therapeutics Inc
What is the Intrinsic Value of one 17R stock?
The intrinsic value for Travere Therapeutics Inc (17R) under the Base Case is 18.83 EUR.
Is 17R stock undervalued or overvalued?
Compared with the current market price of 20.4 EUR, the stock appears Overvalued by 8% .
